2019 saw many noteworthy changes in the regulatory industry. In April 2019 it was announced that the FDA’s Office of New Drugs (OND) would create enhanced review zones that would intersect disease areas and divisions, to maximise access to more focused and innovative areas of regulatory expertise. While this article is by no means an exhaustive listing of all the changes globally, Aman Khera at Worldwide Clinical Trials seeks to provide the reader with an insightful snapshot of a selection of the changes that have impacted the industry last year and how they’ll impact 2020.